Nyrada raises A$12m in placement for Xolatryp Phase IIa
Nyrada (ASX:NYR) raised A$12.0 million via a placement of about 19.4 million CHESS Depositary Instruments (CDIs) priced at A$0.62 per CDI, and will target an additional A$2.0m via a securities purchase plan. Proceeds are for development of lead drug candidate Xolatryp and pipeline expansion.
Nyrada ASX:NYR has raised A$12.0 million through a placement of approximately 19.4 million CHESS Depositary Instruments (CDIs) and will target a further A$2.0m through a securities purchase plan to fund development of its lead drug candidate Xolatryp.The placement was priced at A$0.62 per CDI, repr…